In March 2017, for the first time in decades, treatment options for anal cancer patients cancers leapt forward.
Results from a study out of MD Anderson showed that metastatic anal cancer patients had an enormous response rate (24%) to a new immunotherapy compound called Nivolumab. Further, the drug was well tolerated with minimal side effects.
The research was published in the Lancet, one of the most renown medical journals in the world. An ACF grant co-funded the study.
Immunotherapies are showing great promise. With more new immunotherapies in the research pipeline, treatment for anal cancer is finally advancing past the antiquated standards set in the 1970s.
The next set of studies will be look at combining the new compound with additional immunotherapy drugs and other chemotherapy agents to strengthen interactions. If you feel as though you may be a good candidate for these trials, or would like to know how to get access to the drug, please contact us. Otherwise, sign up for our newsletter to stay up to date on these exciting achievements and be a part of making history.
We’re here to empower thrivers and the anal cancer community. But we can’t do it without your support.
